Management of alemtuzumab-induced Graves’ disease in pregnancy: a case report and literature review
BackgroundAlemtuzumab (ALZ), a monoclonal antibody used to treat relapsing-remitting multiple sclerosis (RRMS), is associated with a high risk of autoimmune thyroid disorders, particularly Graves’ disease (GD). Managing ALZ-induced GD during pregnancy …